Yarrow (YARW) news

Bellevue Group AG reports 10.6% passive stake in Yarrow Bioscience as of Sept 10 - SEC filing

Bellevue Group AG has disclosed a 10.6% passive stake in Yarrow Bioscience as of September 10, 2026, according to a recent SEC filing. The investment, which does not confer voting rights or influence over the company’s operations, is categorized as a passive holding. The filing indicates that the…

Yarrow Bioscience offering prices $26.00/shr

Yarrow Bioscience (YARW) is a clinical-stage biotechnology company focused on developing therapies for autoimmune thyroid diseases, including Graves disease (GD) and thyroid eye disease (TED). The company is currently developing YB-101 monoclonal antibody therapy , a monoclonal antibody therapy…

Yarrow Bioscience is said to offer shares for $26 each

Yarrow Bioscience has announced an initial public offering (IPO) with shares being offered at $26 each, according to recent filings with the Securities and Exchange Commission [1]. The company, which focuses on biotechnology and pharmaceutical development, aims to raise capital to support ongoing…

Yarrow Bioscience announces proposed underwritten public offering

Yarrow Bioscience, Inc. (Nasdaq: YARW) has announced the completion of its merger with VYNE Therapeutics Inc., marking a significant step in the development of its lead product candidate, YB-101, a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody. The…

Yarrow Bioscience Inc: net loss totaled $6.5 million for the second quarter of 2026